145 related articles for article (PubMed ID: 36707253)
1. Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools.
Cai T; Shi L; Guo H; Li R; Cao W; Shen L; Zhu M; Tao Y
Drug Metab Dispos; 2023 May; 51(5):591-598. PubMed ID: 36707253
[TBL] [Abstract][Full Text] [Related]
2. Reductive Desulfuration as an Important Tool in Detection of Small Molecule Modifications to Payload of Antibody Drug Conjugates.
Wang J; Zhang W; Salter R; Lim HK
Anal Chem; 2019 Feb; 91(3):2368-2375. PubMed ID: 30609358
[TBL] [Abstract][Full Text] [Related]
3. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
[TBL] [Abstract][Full Text] [Related]
4. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry.
Inoue K; Mochizuki T; Kasamori N; Komori T
Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963
[TBL] [Abstract][Full Text] [Related]
5. SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.
Hamblett KJ; Jacob AP; Gurgel JL; Tometsko ME; Rock BM; Patel SK; Milburn RR; Siu S; Ragan SP; Rock DA; Borths CJ; O'Neill JW; Chang WS; Weidner MF; Bio MM; Quon KC; Fanslow WC
Cancer Res; 2015 Dec; 75(24):5329-40. PubMed ID: 26631267
[TBL] [Abstract][Full Text] [Related]
6. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
[TBL] [Abstract][Full Text] [Related]
7. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
[TBL] [Abstract][Full Text] [Related]
8. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
9. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
11. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
12. Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3.
Tomabechi R; Miyasato M; Sato T; Takada T; Higuchi K; Kishimoto H; Shirasaka Y; Inoue K
Mol Pharm; 2023 Jan; 20(1):491-499. PubMed ID: 36458938
[TBL] [Abstract][Full Text] [Related]
13. Simple and Rapid LC-MS/MS Methods for Quantifying Catabolites of Antibody-Drug Conjugates with SMCC Linker.
Li L; Wang C; Wu Y; Dong L; Chen F; Dong K; Song H
J Chromatogr Sci; 2021 Jun; 59(7):642-649. PubMed ID: 33420505
[TBL] [Abstract][Full Text] [Related]
14. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
15. Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry.
Lanshoeft C; Stutz G; Elbast W; Wolf T; Walles M; Stoeckli M; Picard F; Kretz O
Rapid Commun Mass Spectrom; 2016 Apr; 30(7):823-32. PubMed ID: 26969923
[TBL] [Abstract][Full Text] [Related]
16. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
[TBL] [Abstract][Full Text] [Related]
17. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
18. Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.
Luo Q; Chung HH; Borths C; Janson M; Wen J; Joubert MK; Wypych J
Anal Chem; 2016 Jan; 88(1):695-702. PubMed ID: 26629796
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1).
Liu Y; Zhou F; Sang H; Ye H; Chen Q; Yao L; Ni P; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Apr; 137():170-177. PubMed ID: 28131055
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
